Search Results
Your search for John L. Marshall, MD ,John L. Marshall, MD matches 10 pages
Showing 1 - 10Medical Costs and Clinical Value: Playing the Long Game
Even as soaring medical costs strain public and private budgets around the world, patients yearn for therapeutic breakthroughs. Game-changing cancer treatments, emerging antiviral agents, and mRNA vaccines are powerful reminders of medical technology’s potential. But insurance premiums and...
Grateful to Be Alive
Everything about my breast cancer diagnosis, from my presentation to diagnosis, was strange. In the spring of 2006, I was performing my monthly breast self-exam when I felt a hard lump in the upper left quadrant of my left breast. Having lost a good friend to breast cancer 4 years earlier, I was...
The Impact of a Pandemic on Mentorship in Medicine
When advising the younger members of our medical community on career decisions, I always list “access to the best mentorship” as the most important priority. By the time we hit residency, we have all proven ourselves able to extract from a book or a journal the facts essential to the practice of...
2019 ASCO: Survey Finds 'Knowledge Gap' in Molecular Profiling Among Oncologists
A questionnaire aimed at assessing how well community oncologists understand “molecular profiling” results from tumor specimens found that 69% of participants either said they didn't know the answers or they responded incorrectly. In six different clinical scenarios, the oncologists...
Increased Recognition of Colorectal Cancer in Young Adults, Even Those Aged 20 to 29, as Evidence Continues to Accumulate
The incidence of colorectal cancer continues to increase among young adults, with the sharpest increase among those aged 20 to 29, according to a recent article in the Journal of the National Cancer Institute.1 This trend has been called disturbing and ominous, but the widely reported results of...
John L. Marshall, MD, on Issues of Value in Colorectal Cancer Treatment
John L. Marshall, MD, of Georgetown University, discusses how the cost of care affects behavior and decision-making on the part of patients and oncologists.
Expert Point of View: John L. Marshall, MD
The pendulum continues to swing in the treatment of stage II and III colon cancer. Not 5 years ago, our party line was that essentially all patients should receive 6 months of adjuvant FOLFOX (leucovorin, fluorouracil [5-FU], oxaliplatin): patients with stage II or III disease, whether rectal or...
Looking for Drivers in the Rearview Mirror
The latest clinical trial looking at combining vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) inhibition in metastatic colorectal cancer adds little to our overall understanding of the mechanisms for optimizing selection of patients to receive such therapies....
Colorectal Cancer 2015
Despite advances in detection and treatment, colorectal cancer remains the third deadliest cancer among men and women in the United States. To get a better understanding of the current state of this disease and what lies ahead, The ASCO Post recently spoke with colorectal cancer expert John L....
Global Leader in Drug Development John L. Marshall, MD, Calls for a Smarter War on Cancer
John L. Marshall, MD, a global leader in the research and treatment of gastrointestinal cancers, grew up in Lexington, Kentucky, in a family that put high value on education. As a young boy, science was already on his mind; he enjoyed the explorative nature that chemistry and biology offered....
